Lysando AG created the Artilysin® platform technology
to fight multidrug-resistant bacteria in various fields across different
industries. Artilysin®s are muralytic proteins which are active on
gram-positive and gram-negative target bacteria. The technology is continually
developed to meet the expectations of our customers and the addressed markets.